[{"id": 1200468, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Normal phenytoin metabolism"}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Normal Metabolizer"}, "activityscore": {"CYP2C9": "2.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "2"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200469, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "1.5"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200470, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "1"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200471, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "0.5"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200472, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "0"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200473, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "n/a"}, "drugrecommendation": "No recommendation", "classification": "n/a", "phenotypes": {"CYP2C9": "Indeterminate"}, "activityscore": {"CYP2C9": "n/a"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "n/a"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200474, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Normal phenytoin metabolism"}, "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.", "classification": "Strong", "phenotypes": {"CYP2C9": "Normal Metabolizer"}, "activityscore": {"CYP2C9": "2.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "2"}, "population": "PHT naive", "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200475, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."}, "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.", "classification": "Strong", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "1.5"}, "population": "PHT naive", "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200476, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.", "classification": "Strong", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "1"}, "population": "PHT naive", "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200477, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "0.5"}, "population": "PHT naive", "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200545, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "n/a"}, "drugrecommendation": "No recommendation", "classification": "n/a", "phenotypes": {"CYP2C9": "Indeterminate"}, "activityscore": {"CYP2C9": "n/a"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "n/a"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200478, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "0"}, "population": "PHT naive", "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200479, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "n/a"}, "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.", "classification": "Strong", "phenotypes": {"CYP2C9": "Indeterminate"}, "activityscore": {"CYP2C9": "n/a"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "n/a"}, "population": "PHT naive", "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200480, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Normal phenytoin metabolism"}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Normal Metabolizer"}, "activityscore": {"CYP2C9": "2.0"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "2"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200481, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.5"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "1.5"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200482, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.0"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "1"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200483, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.5"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "0.5"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200484, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.0"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "0"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200485, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "n/a"}, "drugrecommendation": "No recommendation", "classification": "n/a", "phenotypes": {"CYP2C9": "Indeterminate"}, "activityscore": {"CYP2C9": "n/a"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "n/a"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200486, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "n/a"}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "No Result"}, "activityscore": {"CYP2C9": "No Result"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "No Result"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200487, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "n/a"}, "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.", "classification": "Strong", "phenotypes": {"CYP2C9": "No Result"}, "activityscore": {"CYP2C9": "No Result"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "No Result"}, "population": "PHT naive", "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200488, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Normal phenytoin metabolism"}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Normal Metabolizer"}, "activityscore": {"CYP2C9": "2.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "2"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200489, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "1.5"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200490, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "1"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200491, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "0.5"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200492, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "0"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200493, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "n/a"}, "drugrecommendation": "No recommendation", "classification": "n/a", "phenotypes": {"CYP2C9": "Indeterminate"}, "activityscore": {"CYP2C9": "n/a"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "n/a"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200494, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Normal phenytoin metabolism"}, "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.", "classification": "Optional", "phenotypes": {"CYP2C9": "Normal Metabolizer"}, "activityscore": {"CYP2C9": "2.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "2"}, "population": "PHT use >3mos", "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200495, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."}, "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.", "classification": "Optional", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "1.5"}, "population": "PHT use >3mos", "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200496, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.", "classification": "Optional", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "1"}, "population": "PHT use >3mos", "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200497, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.", "classification": "Optional", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "0.5"}, "population": "PHT use >3mos", "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200498, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.", "classification": "Optional", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "0"}, "population": "PHT use >3mos", "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200499, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "n/a"}, "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.", "classification": "Optional", "phenotypes": {"CYP2C9": "Indeterminate"}, "activityscore": {"CYP2C9": "n/a"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "n/a"}, "population": "PHT use >3mos", "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200500, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Normal phenytoin metabolism"}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Normal Metabolizer"}, "activityscore": {"CYP2C9": "2.0"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "2"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200501, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.5"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "1.5"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200502, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.0"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "1"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200503, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.5"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "0.5"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200504, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.0"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "0"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200505, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "n/a"}, "drugrecommendation": "No recommendation", "classification": "n/a", "phenotypes": {"CYP2C9": "Indeterminate"}, "activityscore": {"CYP2C9": "n/a"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "n/a"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200506, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "n/a", "CYP2C9": "n/a"}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "No Result"}, "activityscore": {"CYP2C9": "No Result"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "No Result"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200507, "guidelineid": 100412, "drugid": "RxNorm:8183", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "n/a"}, "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.", "classification": "Optional", "phenotypes": {"CYP2C9": "No Result"}, "activityscore": {"CYP2C9": "No Result"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "No Result"}, "population": "PHT use >3mos", "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.", "version": 1, "drug": {"name": "phenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200508, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Normal phenytoin metabolism"}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Normal Metabolizer"}, "activityscore": {"CYP2C9": "2.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "2"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200509, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "1.5"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200510, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "1"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200511, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "0.5"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200512, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "0"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200513, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "n/a"}, "drugrecommendation": "No recommendation", "classification": "n/a", "phenotypes": {"CYP2C9": "Indeterminate"}, "activityscore": {"CYP2C9": "n/a"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "n/a"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200514, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Normal phenytoin metabolism"}, "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.", "classification": "Strong", "phenotypes": {"CYP2C9": "Normal Metabolizer"}, "activityscore": {"CYP2C9": "2.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "2"}, "population": "PHT naive", "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200515, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."}, "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.", "classification": "Strong", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "1.5"}, "population": "PHT naive", "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200516, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.", "classification": "Strong", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "1"}, "population": "PHT naive", "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200517, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "0.5"}, "population": "PHT naive", "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200518, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "0"}, "population": "PHT naive", "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200519, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "n/a"}, "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.", "classification": "Strong", "phenotypes": {"CYP2C9": "Indeterminate"}, "activityscore": {"CYP2C9": "n/a"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "n/a"}, "population": "PHT naive", "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200520, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Normal phenytoin metabolism"}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Normal Metabolizer"}, "activityscore": {"CYP2C9": "2.0"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "2"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200521, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.5"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "1.5"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200522, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.0"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "1"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200546, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "n/a"}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "No Result"}, "activityscore": {"CYP2C9": "No Result"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "No Result"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200523, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.5"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "0.5"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200524, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.0"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "0"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200525, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "n/a"}, "drugrecommendation": "No recommendation", "classification": "n/a", "phenotypes": {"CYP2C9": "Indeterminate"}, "activityscore": {"CYP2C9": "n/a"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "n/a"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200526, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "n/a"}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "No Result"}, "activityscore": {"CYP2C9": "No Result"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "No Result"}, "population": "PHT naive", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200527, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "n/a"}, "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.", "classification": "Strong", "phenotypes": {"CYP2C9": "No Result"}, "activityscore": {"CYP2C9": "No Result"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "No Result"}, "population": "PHT naive", "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200528, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Normal phenytoin metabolism"}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Normal Metabolizer"}, "activityscore": {"CYP2C9": "2.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "2"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200529, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "1.5"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200530, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "1"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200531, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "0.5"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200532, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "0"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200533, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "n/a"}, "drugrecommendation": "No recommendation", "classification": "n/a", "phenotypes": {"CYP2C9": "Indeterminate"}, "activityscore": {"CYP2C9": "n/a"}, "allelestatus": {"HLA-B": "HLA-B*15:02 negative"}, "lookupkey": {"HLA-B": "*15:02 negative", "CYP2C9": "n/a"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200534, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Normal phenytoin metabolism"}, "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.", "classification": "Optional", "phenotypes": {"CYP2C9": "Normal Metabolizer"}, "activityscore": {"CYP2C9": "2.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "2"}, "population": "PHT use >3mos", "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200535, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."}, "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.", "classification": "Optional", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "1.5"}, "population": "PHT use >3mos", "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200536, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.", "classification": "Optional", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "1"}, "population": "PHT use >3mos", "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200537, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.", "classification": "Optional", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.5"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "0.5"}, "population": "PHT use >3mos", "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200538, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.", "classification": "Optional", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.0"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "0"}, "population": "PHT use >3mos", "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200539, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "n/a"}, "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.", "classification": "Optional", "phenotypes": {"CYP2C9": "Indeterminate"}, "activityscore": {"CYP2C9": "n/a"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "n/a"}, "population": "PHT use >3mos", "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200540, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Normal phenytoin metabolism"}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Normal Metabolizer"}, "activityscore": {"CYP2C9": "2.0"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "2"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200541, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."}, "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.5"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "1.5"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200542, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Moderate", "phenotypes": {"CYP2C9": "Intermediate Metabolizer"}, "activityscore": {"CYP2C9": "1.0"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "1"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200543, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.5"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "0.5"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200544, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "n/a", "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."}, "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.", "classification": "Strong", "phenotypes": {"CYP2C9": "Poor Metabolizer"}, "activityscore": {"CYP2C9": "0.0"}, "allelestatus": {"HLA-B": "No HLA-B Result"}, "lookupkey": {"HLA-B": "No Result", "CYP2C9": "0"}, "population": "PHT use >3mos", "comments": "n/a", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}, {"id": 1200547, "guidelineid": 100412, "drugid": "RxNorm:72236", "implications": {"HLA-B": "Increased risk of phenytoin-induced SJS/TEN", "CYP2C9": "n/a"}, "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.", "classification": "Optional", "phenotypes": {"CYP2C9": "No Result"}, "activityscore": {"CYP2C9": "No Result"}, "allelestatus": {"HLA-B": "HLA-B*15:02 positive"}, "lookupkey": {"HLA-B": "*15:02 positive", "CYP2C9": "No Result"}, "population": "PHT use >3mos", "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.", "version": 1, "drug": {"name": "fosphenytoin"}, "guideline": {"name": "CYP2C9, HLA-B and Phenytoin"}}]